Disease · MONDO_0005446

cutaneous leishmaniasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cutaneous leishmaniasis. Diseases, record MONDO_0005446. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005446

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cutaneous leishmaniasis; Open Targets
Open Targets ID: MONDO_0005446; Open Targets
Other names: Asian desert cutaneous leishmaniasis, zone of skin leishmaniasis; Open Targets
Disease Ontology: DOID:9111; Disease Ontology
MeSH: D016773; MeSH
NCI Thesaurus: C34768; NCI Thesaurus
NCI Thesaurus: C34770; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 31 drugs, from DailyMed; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MILTEFOSINE	CHEMBL125	Small molecule	Approval	DailyMed	24	23	23	Drugs and targets
MEGLUMINE ANTIMONATE	CHEMBL239129	Small molecule	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
PAROMOMYCIN	CHEMBL370143	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
SODIUM STIBOGLUCONATE	CHEMBL6067962	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
GENTAMICIN	CHEMBL6067485	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ANTIMONY	CHEMBL4297652	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PENTAMIDINE ISETHIONATE	CHEMBL361506	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/136	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 3	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 3	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 3	https://conductscience.org/library/genes/2983	Drugs and targets
JAK1	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Phase 2/3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Phase 2/3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Phase 2/3	https://conductscience.org/library/genes/3718	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 3	https://conductscience.org/library/genes/4312	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials71

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00471705	Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.	Phase 3	437	2010-07-14	Cutaneous Leishmaniasis	MEGLUMINE ANTIMONATE, MILTEFOSINE	Its record names the disease	ClinicalTrials.gov
NCT00662012	Sodium Stibogluconate Treatment of Leishmaniasis	Phase 2	414	2017-03-09	Leishmaniasis	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT01790659	Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama	Phase 3	399	2017-08-23	Cutaneous Leishmaniasis	PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00606580	Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)	Phase 3	375	2014-07-14	Cutaneous Leishmaniasis	GENTAMICIN, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00703924	Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World	Phase 2	92	2017-02-15	Cutaneous Leishmaniasis	GENTAMICIN, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00657618	Use of Sodium Stibogluconate as a Treatment for Leishmaniasis	Phase 1/2	77	2018-02-27	Leishmaniasis	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT00884377	Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis	Phase 2	56	2017-07-14	Cutaneous Leishmaniasis	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT01494350	WR 279,396 Open Label Treatment Protocol in Tunisia	Phase 2	50	2014-12-19	Cutaneous Leishmaniasis	GENTAMICIN, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01536795	A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis	Phase 2	48	2021-01-07	Old World Cutaneous Leishmaniasis	GENTAMICIN SULFATE, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01032382	Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)	Phase 2	30	2014-08-22	Leishmaniasis, Cutaneous	GENTAMICIN, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 71

See all 71 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
WR 279,396 vs Paromomycin: deaths from any cause	0 of 201	0 of 198	399	NCT01790659	Trial comparisons
WR 279,396 vs Paromomycin: serious adverse events	2 of 201	1 of 198	399	NCT01790659	Trial comparisons
WR 279,396 vs Placebo: Rate of Relapse	0 of 50	3 of 42	92	NCT00703924	Trial comparisons
WR 279,396 vs Placebo: serious adverse events	1 of 50	0 of 42	92	NCT00703924	Trial comparisons
Sodium Stibogluconate Intravenous vs ThermoMed Device: deaths from any cause	0 of 28	0 of 28	56	NCT00884377	Trial comparisons
Sodium Stibogluconate Intravenous vs ThermoMed Device: serious adverse events	5 of 28	2 of 28	56	NCT00884377	Trial comparisons
WR279,396 With Tegaderm Dressing vs WR279,396 With Gauze and Tape Dressing: deaths from any cause	0 of 24	0 of 24	48	NCT01536795	Trial comparisons
WR279,396 With Tegaderm Dressing vs WR279,396 With Gauze and Tape Dressing: serious adverse events	0 of 24	0 of 24	48	NCT01536795	Trial comparisons
Paromomycin Alone Treatment vs WR 279,396: Final Clinical Cure for Index Lesions	11 of 16	9 of 14	30	NCT01032382	Trial comparisons
Paromomycin Alone Treatment vs WR 279,396: serious adverse events	0 of 16	0 of 14	30	NCT01032382	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials27

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30815688	RESULT	1	PubMed
20438389	RESULT	1	PubMed
19415122	RESULT	1	PubMed
11353640	RESULT	1	PubMed
39147194	DERIVED	1	PubMed
35255096	DERIVED	1	PubMed
34048461	DERIVED	1	PubMed
33253864	DERIVED	1	PubMed
32894278	DERIVED	1	PubMed
30379814	DERIVED	1	PubMed

1 to 10 of 27

See all 27 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005446

GET https://conductscience.org/api/diseases/v1/MONDO_0005446/drugs?page=2

API reference For AI assistants